Absci (NASDAQ:ABSI - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Absci to post earnings of ($0.19) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
Absci (NASDAQ:ABSI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The firm had revenue of $1.27 million for the quarter, compared to analyst estimates of $2.05 million. Absci had a negative return on equity of 44.24% and a negative net margin of 2,838.89%. During the same quarter last year, the firm earned ($0.27) EPS. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Absci Stock Up 1.3 %
Shares of Absci stock traded up $0.05 during trading on Tuesday, hitting $4.05. 700,403 shares of the stock were exchanged, compared to its average volume of 1,316,156. The stock has a market cap of $459.92 million, a price-to-earnings ratio of -4.31 and a beta of 2.18. The firm's 50-day moving average price is $4.01 and its 200 day moving average price is $4.11. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.49 and a quick ratio of 6.49. Absci has a 12-month low of $1.18 and a 12-month high of $6.72.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ABSI. Guggenheim began coverage on Absci in a report on Wednesday, October 2nd. They issued a "buy" rating and a $10.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Absci in a report on Thursday, August 15th. Finally, KeyCorp lowered their target price on shares of Absci from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $8.67.
View Our Latest Analysis on Absci
Absci Company Profile
(
Get Free Report)
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Further Reading
Before you consider Absci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.
While Absci currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.